EU states to receive 100m extra doses of Pfizer-BioNTech vaccine

pharmafile | January 4, 2021 | News story | Sales and Marketing COVID-19, EU, Pfizer, Vaccine 

Pfizer and BioNTech have announced they will supply an additional 100 million doses of their COVID-19 vaccine, COMIRNATY, to the EU’s 27 member states in 2021.

The announcement, a result of the European Commission’s decision to exercise its option to purchase a further 100 million doses under its Advanced Purchase Agreement, brings the total number of vaccine doses to be delivered to the EU to 300 million.

Albert Bourla, Chairman and Chief Executive Officer of Pfizer, said: “We remain committed to moving as quickly and safely as possible to bring this vaccine to more people in Europe, as the deadly virus continues to spread at an alarming rate.

“In partnership with the European Commission, member states and healthcare providers, we will be able to reach a total of 150 million Europeans across the continent.”

Dr Ugur Sahin, CEO and Co-founder of BioNTech, added: “The additional 100 million doses will be delivered in 2021 supporting the vaccination campaigns which started two days ago in all 27 member states.

“Our goal remains to bring a safe and effective COVID-19 vaccine to as many people as we can all around the world.”

The European Medicines Agency approved the Pfizer-BioNTech jab for use in EU states in late December last year, following authorisations for the vaccine’s use in the UK and the US.

Darcy Jimenez

Related Content

Daiichi Sankyo’s Vanflyta approved by EC for acute myeloid leukaemia treatment

Daiichi Sankyo has announced that Vanflyta (quizartinib) has been approved in the EU for combination …

GSK shares new data for RSV vaccine Arexvy

GSK announced positive results from its phase 3 trial which assessed the immune response and …

GSK and Zhifei partner for shingles vaccine promotion in China

GSK has announced that it has come to an exclusive agreement with Chingqing Zhifei Biological …

Latest content